Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2099 of 6351
-
MRI-Guided radiation aims to cut side effects in prostate cancer treatment
Disease control OngoingThis study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostatic lesions. In patients without identifiable prostate cancer lesions, SBRT to t…
Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise against rare salivary gland cancer
Disease control OngoingThe purpose of this study is to find out what effects, good and/or bad, the drug lenvatinib has on the patient and on adenoid cystic carcinoma. This type of cancer study is called a phase II study. Researchers hope to learn if the study drug will shrink the cancer by at least one…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo shows promise for slowing lymphoma growth
Disease control OngoingThis phase II trial studies how well ixazomib citrate and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that grows slowly (indolent). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a prostate cancer drug help fight a tough breast cancer?
Disease control OngoingThis trial is designed to determine the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple negative breast cancer (TNBC).
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Shorter proton therapy after mastectomy shows promise in reducing side effects
Symptom relief CompletedThis is a randomized controlled trial to determine the safety of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation. Proton therapy is recognized as a standard option for the delivery of radiothera…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New drug shows promise for lupus kidney patients
Disease control CompletedThe overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, …
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control By invitation onlyThis phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vac…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough lung cancer in early trial
Disease control OngoingThis phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a period of improvement (recurrent) and who have progress…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with PTEN mutation
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Re…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New scan could reveal which breast cancer patients will respond to hormone therapy
Diagnosis OngoingThis phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New heart procedure may reduce stroke risk without blood thinners
Disease control CompletedStudy category and Rationale Clinical study, Category A. Clinical Phase: Post market study Background and Rationale: Left atrial appendage occlusion (LAAO) allows avoiding oral anticoagulation and provides at the same time an at least equally good protection from strokes and pe…
Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a small breathing hurdle ease sleep apnea?
Disease control CancelledObstructive sleep apnea (OSA) is inherently site-specific. In a physiological controlled intervention study, the investigators seek to determine whether applying expiratory resistance can acutely improve ventilation and sleep in patients with expiratory flow limitation (EFL).
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
Lung cancer trial aims to zap tumors harder
Disease control OngoingA randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conven…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 26, 2026 18:12 UTC
-
Hidden heart genes may trigger sudden death in epilepsy patients
Knowledge-focused Recruiting nowEpilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood b…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:07 UTC
-
Can blood and urine markers reveal how rare kidney diseases progress?
Knowledge-focused Recruiting nowThe purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxalu…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can AI-Guided ultrasound make spinal anesthesia safer?
Knowledge-focused OngoingThe overall aim of this study is to develop an automated spinal landmark identification system to improve patient safety and efficacy of neuraxial procedure needle insertion success. This is a prospective cohort study to evaluate the accuracy of the automated spinal landmark ide…
Sponsor: KK Women's and Children's Hospital • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New combo therapy aims to save more breasts in High-Risk cancer
Disease control Stopped earlyIn the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and surviva…
Phase 1/2 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can less radiation be enough? new trial aims to cut side effects for HPV-linked throat cancer
Disease control OngoingThe purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could gum disease fuel inflammation in heart transplants?
Knowledge-focused CompletedInflammation plays a key role in the deterioration of chronic heart transplants. Periodontal disease is not limited to the tooth-supporting structures - it also contributes to systemic inflammation. This study explored whether periodontitis is associated with serum high-sensitivi…
Sponsor: Baskent University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Whole-Body MRI may outshine standard scans for prostate cancer staging
Diagnosis OngoingThis trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer. Diagnostic procedures, such as magnetic resonance whole body diffus…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC